Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news

The unusual access to an experimental drug has captured the attention of the American public as well.

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week's "Readout LOUD."

Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news